Denali Therapeutics Inc. (NASDAQ:DNLI) price on Friday, August 06, fall -1.66% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $52.05.
A look at the stock’s price movement, the close in the last trading session was $52.93, moving within a range at $51.68 and $53.38. The beta value (5-Year monthly) was 1.93 while the PE ratio in trailing twelve months stood at 385.56. Turning to its 52-week performance, $93.94 and $28.62 were the 52-week high and 52-week low respectively. Overall, DNLI moved -29.76% over the past month.
Denali Therapeutics Inc.’s market cap currently stands at around $6.30 billion, with investors looking forward to this quarter’s earnings report slated for Nov 03, 2021 – Nov 08, 2021. Analysts project the company’s earnings per share (EPS) to be -$0.4, which has seen fiscal year 2021 EPS growth forecast to increase to -$1.78 and about -$2.06 for fiscal year 2022. Per the data, EPS growth is expected to be -382.50% for 2021 and -15.70% for the next financial year.
Analysts have a consensus estimate of $29.35 million for the company’s revenue for the quarter, with a low and high estimate of $5.61 million and $65 million respectively. The average forecast suggests up to a 676.50% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $100.28 million, representing a -70.10% decline on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that DNLI is a 100% Sell. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
12 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 9 recommend DNLI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Overweight which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
DNLI’s current price about -12.30% and -22.26% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 31.40, while 7-day volatility ratio is 4.26% and 5.96% in the 30-day chart. Further, Denali Therapeutics Inc. (DNLI) has a beta value of 1.85, and an average true range (ATR) of 3.38. Analysts have given the company’s stock an average 52-week price target of $86.10, forecast between a low of $60.00 and high of $112.00. Looking at the price targets, the low is -15.27% off current price level while to achieve the yearly target high, price needs to move -115.18%. Nonetheless, investors will most likely welcome a -60.42% jump to $83.50 which is the analysts’ median price.
In the market, a comparison of Denali Therapeutics Inc. (DNLI) and its peers suggest the former has performed considerably weaker. Data shows DNLI’s intraday price has changed -1.66% in last session and 64.40% over the past year. Comparatively, Pieris Pharmaceuticals Inc. (PIRS) has moved 1.06% on the day and only 37.68% in the past 12 months. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.17% and 0.41% respectively in the last trading.
If we refocus on Denali Therapeutics Inc. (NASDAQ:DNLI), historical trading data shows that trading volumes averaged 0.53 million over the past 10 days and 666.53K over the past 3 months. The company’s latest data on shares outstanding shows there are 120.89 million shares.
The 2.60% of Denali Therapeutics Inc.’s shares are in the hands of company insiders while institutional holders own 76.70% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.48 million on Apr 14, 2021, giving us a short ratio of 13.68. The data shows that as of Apr 14, 2021 short interest in Denali Therapeutics Inc. (DNLI) stood at 5.34% of shares outstanding, with shares short falling to 6.67 million registered in Mar 14, 2021. Current price change has pushed the stock -37.86% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the DNLI stock continues to rise going into the next quarter.